Irritable Bowel Syndrome

A combination of first-line management consisting of validation, explanation, and a positive diagnosis, non-pharmacological treatments, and pharmacological treatment should be considered for pediatric patients with IBS or functional abdominal pain disorders.

Patients with irritable bowel syndrome more frequently self-reported non-celiac gluten sensitivity compared to the control group, as well as major gastrointestinal symptoms found in the study included bloating, abdominal discomfort, and belching.

There were no associations found between infantile colic and the risk of developing functional gastrointestinal disorders at age 4-6.

In a study presented at ACG, investigators focus on quality of life improvements for patients with irritable bowel syndrome.

Students with IBS were also linked to depression and anxiety symptoms.

Dr. Aljaras talks about the importance of focusing on diet when examining irritable bowel syndrome.

Taste scores were significantly correlated with depression scores for both patients with irritable bowel syndrome and functional constipation.

IBS is considered 1 of the most expensive conditions in gastroenterology.

Data show patients with chronic IBS had six times the odds of developing glaucoma (OR 6.58; 95% CI, 2.00 - 16.89), in comparison to those without chronic IBS.

Advice for community physicians and gastroenterologists to help manage patients with ulcerative colitis.

Drs Maria T. Abreu and Timothy Ritter comment on limitations faced by providers who treat patients with ulcerative colitis and highlight strategies under investigation that can improve how the disease is managed.

Implications for treating patients with ulcerative colitis with novel S1P receptor modulators based on data revealed by the phase 2 OASIS trial, which has now led to a phase 3 study, ELEVATE UC 52.

Limitations that physicians and patients face when selecting therapy for ulcerative colitis.

Drs Maria T. Abreu and Andres Yarur briefly review current treatment options used to manage patients with ulcerative colitis.

Maria T. Abreu, MD, of the University of Miami Health System, explains how goals of treatment for ulcerative colitis have changed in recent years and reacts to changes in managing the disease.

Treatment recommendations for patients with ulcerative colitis as outlined by the American College of Gastroenterology clinical practice guidelines.

Andres Yarur, MD, of the Medical College of Wisconsin, comments on the chronic, progressive nature of ulcerative colitis and highlights special considerations for classifying patients based on disease severity.

Current treatment limitations in inflammatory bowel disease and the rationale for earlier initiation and use of newer therapies to manage pediatric and adult patients.

Drs Marla Dubinsky and Stephen B. Hanauer react to newer therapies currently being explored for inflammatory bowel disease and discuss where each may fit into future therapeutic algorithms.

A large proportion of IBS-C patients did not seek health care during the COVID-19 pandemic despite symptoms.

The significance of conducting future head-to-head trials of therapies used to treat inflammatory bowel disease and implications for treating ulcerative colitis (UC) with vedolizumab based on recent data demonstrated when the drug was tested in a first-ever head-to-head biologic clinical study in UC.

The rationale for treating inflammatory bowel disease with ustekimumab based on more recent safety and efficacy data demonstrated by a trial that followed patients for up to 5 years.

Sucrase isomaltase deficiency is often overlooked symptom in adult patients with IBS-D.

Data show nearly 1 in 10 patients with IBS-D in study were identified with SID.

Data show clinically meaningful improvement in IBDQ score and MCS score in patients treated with UST.

Data show a 23.5% increase in influenza vaccination rates.

Data show biologic therapy was not associated with ICU admission or death due to infection.

Linaclotide has been marketed as LINZESS to treat irritable bowel syndrome with constipation.